Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | FNTA | P49354 | 13/20 | 0.33 |
| ▸ | FNTB | P49356 | 13/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 8/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Methylhistamine SCHEMBL196356 | 0.83 | — | — | |
| N-Methylhistamine SCHEMBL27340947 | 0.83 | — | — | |
| SCHEMBL946729 | 0.83 | — | — | |
| N-Methylhistamine SCHEMBL2183879 | 0.82 | TDP1 (1.00) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| N-Methylhistamine SCHEMBL1320841 | 0.82 | TDP1 (1.00) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| N-Methylhistamine SCHEMBL19951025 | 0.82 | HRH4 (0.96) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| Hydrochloric Acid SCHEMBL3001559 | 0.82 | TDP1 (0.41) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| Hydrochloric Acid SCHEMBL6773706 | 0.82 | TDP1 (0.41) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL2171709 | 0.73 | CHRM5 (0.37) | CYP2C9CYP2C19HRH4HRH3CHRM5 | |
| SCHEMBL14416066 | 0.73 | CYP2C9 (0.78) | CYP2C9TSHRCYP2C19MTORHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190709-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2023-06-22 | — | — | US | disclosed |